This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
What's in Store for Teladoc's (TDOC) Q4 Earnings?
by Zacks Equity Research
Teladoc's (TDOC) Q4 earnings might suffer high expenses, partly offset by rise in revenues.
Amicus Therapeutics (FOLD) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Amicus Therapeutics (FOLD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tenet Healthcare (THC) Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Tenet Healthcare's (THC) Q4 earnings are likely to suffer lower admissions due to divestitures.
Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Zoetis Inc. (ZTS) is gearing up to report fourth-quarter 2018 results. The company continues to strengthen its diverse product portfolio through lifecycle innovations, strong customer relationships, and access to new markets and technologies.
Amicus (FOLD) Boasts Strong Pipeline Amid Stiff Competition
by Zacks Equity Research
Amicus (FOLD) is well placed after the United States approved its only marketed drug, Galafold, and the company added 14 new gene therapy programs to its pipeline for rare metabolic diseases.
Amicus Therapeutics (FOLD) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -14.81% and -11.63%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Amicus Therapeutics (FOLD) Catches Eye: Stock Jumps 6.7%
by Zacks Equity Research
Amicus Therapeutics (FOLD) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Amicus (FOLD) Gets FDA Nod for Fabry Disease Drug Galafold
by Zacks Equity Research
Amicus (FOLD) gets a major boost with the FDA approval of lead candidate, Galafold (migalastat) 123 mg capsules for the treatment of Fabry disease.
Amicus Therapeutics (FOLD) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of 0.00% and 12.65%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for Amicus Therapeutics (FOLD) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Amicus Therapeutics (FOLD) stock based on the movements in the options market lately.
Amicus Therapeutics (FOLD) Surges: Stock Moves 9.2% Higher
by Zacks Equity Research
Amicus Therapeutics (FOLD) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Should You Sell Amicus Therapeutics, Inc. (FOLD) Before Earnings?
by Zacks Equity Research
Amicus Therapeutics, Inc. (FOLD) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Amicus Therapeutics (FOLD) Soars: Stock Adds 9.2% in Session
by Zacks Equity Research
Amicus Therapeutics (FOLD) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Options Traders Expect Huge Moves in Amicus Therapeutics (FOLD) Stock
by Zacks Equity Research
Amicus Therapeutics (FOLD) needs Investors to pay close attention to the stock based on moves in the options market lately.
Company News for July 12, 2017
by Zacks Equity Research
Companies in the News are: FOLD,SLP,ARNA,EVGN,MON
Amicus Therapeutics (FOLD) Catches Eye: Stock Jumps 7.3%
by Zacks Equity Research
Amicus Therapeutics, Inc. (FOLD) was a big mover last session, as the company saw its shares rise over 7% on the day.
Amicus Provides Regulatory Update on Fabry Disease Drug
by Zacks Equity Research
Amicus Therapeutics, Inc. (FOLD) issued an update on the regulatory pathway for migalastat for the treatment of Fabry disease in the U.S.